comparemela.com

Latest Breaking News On - Third pole therapeutics inc - Page 1 : comparemela.com

Third Pole Therapeutics Closes $25M Financing - eNOfit™ Wearable Device Now Ready for Clinical Trials

/PRNewswire/ Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has.

Third Pole Therapeutics Closes $25M Financing - eNOfit™ Wearable Device Now Ready for Clinical Trials

/PRNewswire/ Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has.

Third Pole Therapeutics to Participate in H C Wainwright BioConnect and BIO Partnering at JPM during J P Morgan 40th Annual Healthcare Conference

Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L P

Share this article Share this article WALTHAM, Mass., April 15, 2021 /PRNewswire/  Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has entered into a $15 million debt facility with Avenue Venture Opportunities Fund, L.P. ( Avenue Venture Fund ). We are pleased to partner with Avenue Venture Fund and their team as we achieve some of the most significant milestones in our company s history. This non-dilutive funding will support validation testing of the first tankless iNO (inhaled nitric oxide) wearable device for home use, said Bill Athenson, Third Pole s CEO. We appreciate Avenue s confidence in our late-stage FDA designated breakthrough  hospital and wearable platforms that deliver portable iNO therapies from hospital to home.

Third Pole Therapeutics Expands Board of Directors

Third Pole Therapeutics Expands Board of Directors Veteran Pharmaceutical Industry Executives William Heiden and Werner Cautreels, Ph.D., Add Critical Expertise News provided by Share this article Share this article WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/  Third Pole, Inc., a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced today that it has added two seasoned pharmaceutical executives to its Board of Directors, William Heiden, former CEO and Director of AMAG Pharmaceuticals, and Werner Cautreels, Ph.D., former CEO of Selecta Biosciences. Third Pole is at an exciting juncture with the Series B financing nearing completion and a strong corporate partner in place, said Bill Athenson, Third Pole s CEO.    Mr. Heiden and Dr. Cautreels each brings important strategic acumen and a tremendous set of highly leverageable relevant business experiences to our board. They are joining at a perfect time to support impor

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.